Literature DB >> 25559328

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

Tarek Hassanein1, Karen D Sims2, Michael Bennett3, Norman Gitlin4, Eric Lawitz5, Tuan Nguyen6, Lynn Webster7, Zobair Younossi8, Howard Schwartz9, Paul J Thuluvath10, Helen Zhou11, Bhaskar Rege2, Fiona McPhee12, Nannan Zhou12, Megan Wind-Rotolo11, Ellen Chung2, Amber Griffies2, Dennis M Grasela2, David F Gardiner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25559328     DOI： 10.1016/j.jhep.2014.12.025

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  15 in total

Review 1.  Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.

Authors:  Vinicius L Ferreira; Fernanda S Tonin; Nayara A Assis Jarek; Yohanna Ramires; Roberto Pontarolo
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

2.  Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.

Authors:  Koichi Takaguchi; Hidenori Toyoda; Akemi Tsutsui; Yoshiyuki Suzuki; Makoto Nakamuta; Michio Imamura; Tomonori Senoh; Takuya Nagano; Toshifumi Tada; Yoshihiko Tachi; Atsushi Hiraoka; Kojiro Michitaka; Hiroshi Shibata; Kouji Joko; Hironao Okubo; Kunihiko Tsuji; Shintaro Takaki; Tsunamasa Watanabe; Chikara Ogawa; Kazuaki Chayama; Takashi Kumada; Masatoshi Kudo; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2019-03-08       Impact factor: 7.527

Review 3.  New approaches in the treatment of hepatitis C.

Authors:  Rocío González-Grande; Miguel Jiménez-Pérez; Carolina González Arjona; José Mostazo Torres
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

Review 4.  Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.

Authors:  Sheng-Shun Yang; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-11-05       Impact factor: 6.047

Review 5.  Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.

Authors:  Masao Omata; Tatsuo Kanda; Osamu Yokosuka; Darrell Crawford; Mamun Al-Mahtab; Lai Wei; Alaaeldin Ibrahim; George K K Lau; Barjesh C Sharma; Saeed S Hamid; Wan-Long Chuang; A Kadir Dokmeci
Journal:  Hepatol Int       Date:  2015-05-05       Impact factor: 9.029

Review 6.  Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy.

Authors:  Bassem Refaat; Ahmed Mohamed Ashshi; Adel Galal El-Shemi; Esam Azhar
Journal:  Mediators Inflamm       Date:  2015-04-19       Impact factor: 4.711

7.  NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.

Authors:  Nannan Zhou; Dennis Hernandez; Joseph Ueland; Xiaoyan Yang; Fei Yu; Karen Sims; Philip D Yin; Fiona McPhee
Journal:  J Infect Dis       Date:  2015-07-13       Impact factor: 5.226

Review 8.  Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis.

Authors:  Seyed Moayed Alavian; Mohammad Saeid Rezaee-Zavareh
Journal:  Hepat Mon       Date:  2016-08-22       Impact factor: 0.660

Review 9.  Interferon-free combination therapies for the treatment of hepatitis C: current insights.

Authors:  Jacinta A Holmes; Alexander J Thompson
Journal:  Hepat Med       Date:  2015-11-02

10.  Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.

Authors:  Gretja Schnell; Rakesh Tripathi; Jill Beyer; Thomas Reisch; Preethi Krishnan; Liangjun Lu; Tatyana Dekhtyar; Coleen Hall; Regis A Vilchez; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.